(Q41185508)

28 September 2017

1 reference

title

Newer treatments for inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

28 September 2017

main subject

1 reference

Stotland BR

1

1 reference

28 September 2017

Lichtenstein GR

series ordinal

2

1 reference

28 September 2017

publication date

1 September 1996

1 reference

Primary Care: Clinics in Office Practice

28 September 2017

published in

1 reference

28 September 2017

volume

23

1 reference

28 September 2017

issue

3

1 reference

28 September 2017

page(s)

577-608

1 reference

An experiment to determine the active therapeutic moiety of sulphasalazine

28 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Sulphasalazine and salicylazosulphadimidine in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Metronidazole in Crohn's disease. A double blind cross-over clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Treatment of refractory ulcerative colitis with cyclosporin enemas

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Systemic absorption from hydrocortisone foam enema in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

A double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Distribution of mesalamine enemas in patients with active distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. The Danish Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Metronidazole in the treatment of chronic proctitis: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Treatment of ulcerative colitis with oral 5-aminosalicyclic acid in patients unable to take sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Methotrexate for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Low-Dose Cyclosporine for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Brief report: non-corticosteroid-associated osteonecrosis of the femoral heads in two patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Pentasa in maintenance treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Suppression of Cell-Mediated Immunity by Metronidazole

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

A comparison of prednisolone enemas with low-dose oral prednisolone in the treatment of acute distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Treatment of diversion colitis with short-chain-fatty acid irrigation

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Controlled trial of azathioprine in chronic ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Testing nicotine gum for ulcerative colitis patients. Experience with single-patient trials

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Rectally administered prednisolone--evidence for a predominantly local action

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Azathioprine and 6-mercaptopurine have a role in the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Drug therapy for inflammatory bowel disease: Part I

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Effect of oral cyclosporin on renal function in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Oral budesonide in active Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Budesonide versus prednisolone retention enemas in active distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

TREATMENT OF ACTIVE CHRONIC HEPATITIS AND LUPOID HEPATITIS WITH 6-MERCAPTOPURINE AND AZOTHIOPRINE

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Intrarectal treatment of 100 cases of ulcerative colitis with prednisolone-21-phosphate enemata.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Parenteral nutrition in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Elemental diet as primary treatment of acute Crohn's disease: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Are antibiotics useful in the management of nontoxic severe ulcerative colitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Is there a role for antibiotics as primary therapy in Crohn's ileitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn's disease: results of an open study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Transdermal nicotine for active ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Treatment of chronic proctosigmoiditis with cyclosporin enemas.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

A controlled trial of azathioprine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

A comparison of budesonide with prednisolone for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Inflammatory bowel disease: nutritional implications and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Double blind, placebo controlled trial of metronidazole in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Ten years' experience with an elemental diet in the management of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Treatment of ulcerative colitis with local hydrocortisone

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Controlled trial of azathioprine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

Cyclosporin A retention enemas in refractory distal ulcerative colitis and 'pouchitis'

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970349-3

7 January 2021

10.1016/S0095-4543(05)70349-3

Identifiers

DOI

1 reference

28 September 2017

1 reference